Toxoplasma and Dendritic Cells

Anaïs F. Poncet, Nicolas Blanchard, Sabrina Marion

Toxoplasma and dendritic cells: an intimate relationship that deserves further scrutiny

Anaïs F. Poncet[1], Nicolas Blanchard[2,*] and Sabrina Marion[1,*]

[1] Centre d'Infection et d'Immunité de Lille, Université de Lille, Inserm U1019, CNRS UMR 8204, CHU Lille, Institut Pasteur de Lille, Lille, France

[2] Centre de Physiopathologie Toulouse Purpan (CPTP), Université de Toulouse, INSERM, CNRS, UPS, Toulouse, France

[*] Correspondence: nicolas.blanchard@inserm.fr (N. Blanchard) and Sabrina.Marion@pasteur-lille.fr (S. Marion)

Keywords

Toxoplasma gondii, dendritic cells, innate sensing, antigen presentation, migration

Abstract

Toxoplasma gondii (*Tg*), an obligate intracellular parasite of the phylum Apicomplexa, infects a wide range of animals including humans. A hallmark of *Tg* infection is the subversion of host responses, which is thought to favor parasite persistence and propagation to new hosts. Recently, a variety of parasite-secreted modulatory effectors have been uncovered in fibroblasts and macrophages but the specific interplay between *Tg* and dendritic cells (DCs) is just beginning to emerge. In this review, we summarize the current knowledge on *Tg*-DC interactions, including innate recognition, cytokine production and antigen presentation, and discuss open questions regarding how *Tg* secreted effectors may shape DC functions to perturb innate and adaptive immunity.

Toxoplasma infection induces robust Th1 and cytotoxic responses

Toxoplasma gondii (*Tg*) is a widespread parasite, infecting a large range of warm-blooded animals including humans who are considered as accidental hosts in the *Tg* life cycle. For optimal transmission, parasites need to preserve their host and strike a delicate balance so that efficient immune responses control the parasite burden, while restricting immunopathology. Possibly reflecting the diversity of its natural hosts, multiple genotypes of *Tg* exist worldwide. Yet most parasites in North America and Europe fall within one of three clonal lineages: type I, II or III, which are also the most studied in laboratory mice [1]. In immune-competent humans, a generally mildly symptomatic acute phase of tachyzoite dissemination is followed by the development of bradyzoite-containing cysts in the brain, leading to life-long persisting infection. Latent *Tg* infection of the brain is now considered as a possibly underestimated cause of behavioral alterations and mental disorders in humans [2,3]. Moreover, in immuno-suppressed individuals, parasite conversion to highly replicative tachyzoites can induce brain tissue damage and fatal acute neuro-inflammation. Congenital infections can also be life-threatening for the developing fetus, causing severe neurological pathologies at birth or milder, ocular toxoplasmosis later in life. When considering laboratory mice, type II and type III parasites typically exhibit a relatively low virulence during acute phase, while type I strains kill their host prematurely due to hyper-inflammation and uncontrolled parasite dissemination, and thus fail to establish latent infections. However, this phenotype only applies in laboratory mice and type I strains can lead to persistent infection in wild mice and possibly other hosts, due to genetic variations in host resistance loci [4,5].

As an obligatory intracellular parasite, *Tg* has the ability to invade all nucleated cells and to reside within a **parasitophorous vacuole (PV**, see Glossary). To modulate cell-intrinsic defenses, the parasite releases effectors into the host through apicomplexan-specific secretory organelles called **rhoptries (ROP)** and **dense granules (GRA)**. These effectors operate in concert to manipulate host cell responses involved in cytokine and chemokine secretion, cell cycle progression, host survival

and metabolic homeostasis [6,7]. Strikingly, while a growing number of effectors dampening cell-autonomous immunity are being characterized, very few effectors promoting parasite latency and preservation of the host have been identified.

During natural oral *Tg* infection, dendritic cells (DCs) (Box 1) are one of the first cell types that encounter parasites in the intestine [8]. DCs are key players in the local activation of cell-mediated immunity against *Tg* by producing IL-12 that activates IFN-γ production by T cells and Natural Killer (NK) cells [9]. T cells play a major role in controlling acute dissemination and keeping chronic cerebral infection under control [9]. While the mechanisms by which *Tg* modulates host responses have been extensively investigated in fibroblasts, monocytes and macrophages [6,7], how DC functions are modulated by the parasite remains ill-defined**.** The consequences of these interactions most likely impact on immuno-modulatory functions of DCs and on T cell activation, and are therefore important for the outcome of infection. Since our current knowledge on these questions mainly derives from the study of mouse models, this review concentrates on mouse studies. One section is also dedicated to emerging findings on the specific responses of human DCs, which substantially differ (e.g. parasite sensing).

Innate recognition of *Tg* by DCs

The Tg Profilin-TLR11/12-IL-12 axis: a major pathway in DC responses in mice

Macrophages and DCs detect and respond to microbial products by **pattern recognition receptors** (**PRRs**), such as Toll-Like Receptors (TLRs). PRR signaling influences multiple biological processes including antigen presentation, cell survival, cytokine production and antimicrobial responses. During *Tg* infection, the molecular processes enabling *Tg* sensing by infected DCs are not fully uncovered.

Pioneer studies reported that upon *Tg* systemic infection, the induction of IL-12 production by macrophages, DCs and neutrophils depends on the signaling molecule MyD88, suggesting a TLR-

mediated microbial detection. Similar to MyD88$^{-/-}$ animals, mice in which MyD88 deletion is restricted to CD11c^{+} DCs fail to control type II *Tg* systemic infection and exhibit a strong decrease in IFN-γ production [10,11], demonstrating the major role of DCs in inducing a protective Th1 immunity. In contrast to macrophages, IL-12 production in DCs downstream of MyD88 was found to be independent from the NFκB pathway but to rely on the transcription factor IRF8 [12] (Figure 1a). TLR11 and TLR12, two endo-lysosomal TLRs, which are able to form heterodimers and are stimulated in an UNC93B1-dependent manner, were then identified as the major players in innate sensing of *Tg* by DCs, via the recognition of *Tg* profilin (*Tg*PRF) (Figure 1a) [13]. Mice deficient in these sensing molecules display a drastic defect in IL-12 production by splenic DCs. Consequently, IFN-γ production is severely impaired and mice become highly susceptible to infection [13–17]. There seems to be a functional specificity between both TLRs, since TLR12 but not TLR11 is involved in IL-12 production by plasmacytoid DCs (pDCs) (Box 1). Similar to DC-MyD88$^{-/-}$ mice, TLR12$^{-/-}$ mice display a more severe susceptibility to infection compared to TLR11$^{-/-}$ mice, which is due to a defect in the early activation of IFN-γ production by NK cells and impaired parasite clearance in the peritoneum [16]. Of note, TLR11/TLR12-mediated recognition of *Tg*PRF only operates in mice and not in humans, in which the ortholog TLR11/12 genes are not functional.

Sensing Tg beyond TLR11 and TLR12

TLR2 and TLR4 represent major mammalian surface TLRs that recognize lipoproteins and liposaccharides derived from bacteria, viruses, fungi and parasites. They can also signal from endosomes after internalization of ligand/receptor complexes. In contrast to macrophages [18], TLR2 and TLR4 were proposed to not operate in murine DCs in the sensing of *Tg* **pathogen-associated molecular patterns** (**PAMPs**) based on the observation that IL-12 production is not altered in splenic DCs of TLR2$^{-/-}$ and TLR4$^{-/-}$ mice injected with soluble tachyzoïte antigens (STAg) [19]. However, the responses of splenic DCs isolated from infected mice or of splenic DCs infected *ex*

vivo with live parasites have not been explored in this study. Along this line, parasite surface adhesins *Tg*MIC1/MIC4 were recently reported to stimulate IL-12 secretion in a TLR2-dependent manner in bone marrow-derived DCs (BMDCs) [20] (Figure 3b). Alterations in the production of additional TLR2-stimulated cytokines, notably type I interferons (IFN-I) [21], or in the regulation of other DCs functions (e.g. antigen presentation [22]) were not examined in TLR2$^{-/-}$ infected BMDCs. Thus, further exploration of TLR2 signaling after *Tg* infection may reveal novel regulatory mechanisms of DCs responses. Most importantly, while TLR2$^{-/-}$, TLR4$^{-/-}$ and TLR9$^{-/-}$ mice infected systemically with *Tg* demonstrate limited susceptibility and modest defects in IL-12 production, severe mortality was demonstrated in the same animals receiving the parasite orally [18,23,24]. Notably, DC maturation and migration to draining mesenteric lymph nodes (MLN) were altered in TLR9$^{-/-}$ mice together with decreased CD4^{+} T cell responses [23]. TLR2, TLR4 and TLR9 were also demonstrated to be essential for the development of efficient IFN-γ responses by T cells in the small intestine after oral infection [23,24]. In addition, parasite-induced damage of the intestinal mucosa is decreased in TLR4$^{-/-}$ mice and in mice treated with broad-spectrum antibiotics, suggesting that mucosal immune responses to *Tg* also rely on the indirect stimulation of DCs by normal gut microflora [25]. Hence, the route of infection likely impacts on the mechanisms of *Tg* innate sensing, which may also differ after oral infection between the different DC subsets present in the intestinal mucosa.

Tg innate sensing in human DCs

Deciphering the respective roles of TLRs in the sensing of *Tg* PAMPs is of particular relevance for human DCs, which lack functional TLR11 and TLR12 genes. In contrast to murine DCs, human monocyte-derived DCs fail to respond to STAgs as well as heat-killed (HK) or fixed parasites [26,27]. The TLRs involved in *Tg* sensing in human DCs are not yet identified, however studies led in human blood-derived monocytes, which are major producers of IL-12 upon infection, revealed

126 that parasite invasion is not essential to trigger cytokine responses. In line, phagocytic uptake of live
127 parasites and the acidification of the resulting phagosome enhance cytokine production compared to
128 **active invasion** (Figure 1b) [27]. When parasite **phagocytosis** (but not adhesion) is inhibited,
129 cytokine responses are abrogated, indicating that surface TLRs are not involved in *Tg* sensing. In
130 addition, as phagocytosis of HK but not irradiated parasites fails to stimulate cytokine production,
131 efficient innate recognition of *Tg* may rely on the detection of heat-labile compounds, possibly
132 parasite RNA [27]. Thus, based on what is known for phagosomes containing inert or microbial
133 antigenic material, phagocytosis of live parasites in human monocytes and DCs may trigger the
134 stimulation of endosomal TLRs following phago-lysosomal fusion, or of cytosolic PRRs after
135 phagosomal membrane disruption [28]. Importantly, as opposed to the mouse context in which the
136 cDC1 dominate the IL-12 response, the human cDC1 are non-responsive to *Tg* infection, and IL-12
137 and TNFα production following *Tg* stimulation is restricted to the cDC2 subset [27].
138
139 *How do PRRs sense parasites residing in intracellular vacuoles?*
140 Even in murine DCs, which have been more extensively studied, the molecular processes of PAMP
141 sensing from vacuolar parasites, remain a conundrum. Using trans-well experiments, Pifer et al.
142 demonstrated that contacts between murine DCs and DCs-depleted splenocytes infected by
143 tachyzoites are not required for TLR11-mediated IL-12 production [13]. This suggests that *Tg*PRF, a
144 cytoskeleton protein localized in the cytosol of parasites, is released into the medium and further
145 internalized by DCs into **endolysosomes**, where TLR11/TLR12 are localized [13] (Figure 1a).
146 Whether *Tg*PRF detection by distant DCs relies on the presence of the protein in apoptotic bodies,
147 necrotic debris, or **exosomes** remains an open question. In line with this idea, two independent
148 studies recently demonstrated an active role of exosomes released by type I and type II tachyzoites in
149 stimulating IL-10, IL-12 and TNF-α production by macrophages *in vitro*. When injected into mice,
150 these exosomes were able to induce specific anti-*Tg* humoral responses and $CD8^+$ T cell-mediated

immunity, suggesting that *Tg* exosome internalization by DCs contributes to MHC-I and MHC-II antigen presentation [29,30]. Furthermore, in correlation with the detection of *Tg*PRF by immune cells "at distance" of infected cells, bystander splenic DCs, which do not contain phagocytosed or invaded parasites, induce high amounts of IL-12 [31]. Yet, one may envision that while TLR11/12 stimulation by *Tg*PRF is critical to trigger IL-12 secretion, active invasion by parasites may activate distinct endosomal TLRs or cytosolic PRRs (Figure 1c and 1d). Cytosolic PRR stimulation would imply a process of *Tg* PAMP export from the PV to the host cytosol, in particular nucleic acids. Although speculative, it is logical to consider that this process may be facilitated by vacuolar membrane breakdown following IFN-γ and STAT1-induced **immunity-related GTPase (IRG)** and **guanylate-binding proteins (GBP)** recruitment at the PV membrane (PVM) [6,32]. Supporting this hypothesis, polymorphic *Tg* ROP18, ROP5 and ROP17 proteins are essential secreted factors localized at the PVM that disrupt IRG/GBP-mediated parasite restriction, albeit in a strain-specific manner (Figure 1c). Type II strains possess an inactive ROP5 allele, which hampers blockade of PV disruption in IFN-γ-activated macrophages (Figure 1d). It is likely that similar mechanisms exist in DCs. In support of this hypothesis, infection of IFN-γ-primed BMDCs by type II, but not by type I, parasites induces the recruitment of ubiquitin and the P62 sequestosome (SQSTM1) at the PVM, via a process dependent on the IRG-regulatory proteins Irgm1/Irgm3 and the autophagy-related proteins (ATG) ATG3, ATG5, ATG7 and ATG16L1 (Box 2). Accumulation of p62 on parasite-containing vacuoles occurs after partial damage by IFN-γ-inducible IRG and GBP and contribute to the cytosolic release of luminal antigens that activate $CD8^+$ T cell responses [33]. In addition, in BMDCs, the infection itself is sufficient to trigger STAT1 phosphorylation and nuclear translocation in a strain-independent manner and these responses are accentuated by the addition of IFN-γ [34] (Figure 1c and 1d). However, parasites impede STAT1 activity by inducing the formation of aberrant transcriptional complexes at the promoter of IFN-stimulated genes (ISGs), such as *Irf1* and *Igtp* [34] (Figure 1c). In macrophages, this inhibitory process is mediated by the *Tg*-secreted effector IST

(inhibitor of STAT1 transcriptional activity) in both type I and type II strain-infected cells [35–37]. Most likely, similar *Tg*IST-mediated inhibitory mechanisms take place in infected DCs, however this remains to be formally established. As previously mentioned, upon IFN-γ stimulation of BMDCs, type II parasites, but not type I parasites, induce Irgm1/Irgm3 recruitment at the PVM, which is not sufficient to induce parasite clearance but triggers partial PV disruption [33]. Although this difference is likely linked to the inactive ROP5-II allele, it is worth mentioning that the distinct *Tg* strains can differentially modulate specific aspects of IFNγ signaling through the polymorphic effector proteins ROP16 and GRA15. In particular, GRA15 from type II strains was reported to up-regulate a certain set of ISGs in human fibroblasts in a STAT1-independent but NF-κB-dependent manner [38] [39].

Therefore, strain–specific induced PV damage may promote *Tg* PAMP export to the host cytosol, resulting in strain-specific innate sensing mechanisms and activation of corresponding downstream pathways. Of particular interest is the activation of the **inflammasome**. NLRP3 activation and IL-1β production in human monocytes and bone marrow-derived macrophages were reported to be specifically triggered by type II strains and dependent on the secretion of *Tg*GRA15 into host cells [40,41]. Whether the inflammasome is activated in *Tg*-infected DCs remains to be addressed.

Finally, although not yet explored in *Tg*-infected immune cells, other mechanisms of microbial sensing may control the immune response outcome. The mitochondrial antiviral-signaling protein (MAVS), stimulated downstream of the nucleic acid cytosolic sensor RIG-I (retinoic acid-inducible gene I) as well as STING (stimulator of interferon genes), downstream of the cGAS sensor, are localized at the mitochondrial membrane and the **endoplasmic reticulum (ER)**, respectively [42] (Figure 1c and 1d). Interestingly, these two compartments tightly associate with the PVM, therefore are likely in direct contact with *Tg* PAMPs. Of note, only type I and type III strains, but not type II strains, were reported to trigger the recruitment of mitochondria at the PVM in human fibroblasts [43]. Additionally, a cell achieves frequent contacts between the ER and late endosomes/lysosomes,

where endosomal TLRs reside [44,45] and the PV has been recently shown to intersect with various endosomal compartments [46]. Hence, mechanisms distinct from PVM damage may promote the delivery of PAMPs from vacuolar parasites into intracellular compartments implicated in microbial innate sensing.

DC cytokine secretion: beyond IL-12

Owing to the crucial role of IL-12 in the induction of the cytotoxic and Th1 responses, most studies have focused on the mechanisms by which splenic DCs secrete this cytokine. Nonetheless, the distinct DC subsets operating during infection may secrete additional cytokines contributing to the regulation of various immune responses (Box 1). This aspect is illustrated by a recent study showing that ISG15 production, a IFN-I stimulated pro-inflammatory molecule, enhances the recruitment of cDC1 specifically producing IL-1β at the site of infection during type II parasite systemic infection [47] (Figure 1d). Along this line, IFN-I play an important role in parasite infections [48,49]. In *Tg*-infected mice, pDCs, which expand after oral infection with type II parasites and play a key role in $CD4^+$ T cell priming, were shown to secrete high levels of IFN-α [16,50]. In contrast, IFN-β is mainly produced by inflammatory monocytes in the MLN and requires parasite phagocytosis [51]. Of note, human DCs actively phagocytose parasites and might therefore trigger IFN-I secretion upon *Tg* infection. In addition, in the mouse, IFN-I serum levels gradually increase during systemic *Tg* infection and the cytokine can be detected in the brain and spleen of infected mice. *Ifnar*$^{-/-}$ (Interferon alpha and beta receptor 1) mice orally infected with *Tg*, have increased parasite loads compared to wild-type mice, correlated with slightly decreased survival [51,52]. Importantly, IFN-I are prominent regulators of cDC1 turnover *in vivo* through a dose-dependent modulation of multiple processes including DC apoptosis, proliferation, migration [53], and maturation [54] as well as their **cross-presentation** efficacy [55]. Hence, the role of IFN-I (via an autocrine effect or produced by surrounding cells) in the modulation of DC functions would deserve further exploration.

Moreover, the immune system associated with the intestinal mucosa comprises distinct lymphoid cells, including antigen-experienced $CD8^+$ and $CD4^+$ T cells and various subsets of innate lymphoid cells (ILCs), which reside in the epithelium and the underlying lamina propria (LP). DCs are central players in determining tolerance *versus* immunity during inflammation and infection. Among the DC subsets in the intestinal LP and MLN, $CD103^+$ DCs play an important role in maintaining intestinal homeostasis and inducing regulatory or effector T cells (Box 1). Two recent studies highlighted the role of IL-22 in gut protection against inflammation-triggered tissue necrosis during *Tg* type II infection [56,57]. DCs being potent regulators of T cell and ILC functions, secretion of cytokines by $CD103^+$ DCs and other DC subsets in the intestinal mucosa may contribute to the establishment of protective $CD4^+$ T cell and ILC responses against immunopathology. These responses may be manipulated by the parasite as suggested by the down-regulation of retinoic acid production previously observed in mucosal DCs [8].

To conclude, while in mice, *Tg*PRF detection by TLR11/12 is critical to trigger the secretion of IL-12 and the IFN-γ response for early parasite clearance, active invasion of DCs by parasites and parasite phagocytosis in human cells likely stimulate additional innate sensing mechanisms, which are not fully unraveled (Figure 1). These distinct mechanisms of *Tg* detection may not only regulate DC secretion of various chemokines and cytokines, but also modulate other DC functions including antigen presentation and T cell priming [58–60]. In addition, it is possible that *Tg* secretes yet to be identified, strain-specific factors that target PRR-induced signaling pathways, impacting on the outcome of inflammatory responses. Finally, based on the diversity of DC phenotypes and functions, it appears essential to explore in more depth the mechanisms of *Tg* innate sensing in the different tissue-resident DC subtypes, notably after oral infection.

Modulation of *Tg* antigen presentation and T cell responses

T cell activation relies on three signals: signal 1 elicited by MHC/peptide complex engagement of the TCR; signal 2 triggered when co-stimulatory receptors (e.g. CD28) bind their ligands (e.g. CD80, CD86) on antigen-presenting cells; and signal 3 integrating the cytokine environment to complete T cell differentiation. Thus, antigen availability, expression of co-stimulatory molecules and cytokine release are critical factors regulating T cell activation and memory formation, that can be targeted by *Tg* to promote parasite dissemination and/or persistence.

Mechanisms of MHC-I presentation by Tg and modulation thereof

Through the process of cross-presentation, MHC-I molecules can present antigenic peptides derived from extracellular sources, including from microorganisms that reside in a phagosome or a vacuole like *Tg*. The pathways by which *Tg* antigens access the MHC-I pathway have been partially unraveled [61]. Active secretion of parasite antigens into the infected host cell is a major requirement for efficient MHC-I presentation [62–65]. Moreover, emerging evidence shows that luminal and membrane-bound antigens follow processing mechanisms that exhibit similarities as well as distinctions. The analogies include the implication of the TAP transporter and the proteasome suggesting that in both cases, antigenic precursors exit the vacuole and reach the host cytosol before loading onto MHC-I molecules [66,67]. For luminal antigens, access to the DC cytosol is facilitated by fusion of vesicles of the host ERGIC onto the vacuole [68] through a mechanism that depends on the soluble NSF attachment protein receptor (SNARE) protein Sec22b [69]. This process promotes the recruitment of components of the ER-Associated Degradation machinery onto the PVM, then allowing retro-translocation of vacuolar antigens to the host cytosol. Intriguingly, Sec22b-mediated ER-PV interactions are not involved in the presentation of the membrane-bound protective GRA6 antigen [70]. Instead, optimal processing of GRA6 requires the epitope to be located at the C-terminus of GRA6 and to protrude into the host cytosol [70,71]. Of note, the protective membrane-bound GRA6 antigen associates with a membranous, tubulo-vesicular **intravacuolar network (IVN)**

generated in the vacuolar space by parasite effectors. In the absence of this network, GRA6 redistributes to the PVM and is presented more efficiently by MHC-I, leading to enhanced $CD8^+$ T cell responses [72]. Thus, by trapping membrane-bound antigens, the network plays a negative modulatory function on recognition of *Tg*-infected cells by $CD8^+$ T cells (Figure 2).

Another way by which the parasite may potentially affect DC antigen presentation capabilities is by redirecting organelles toward the PV. In *Tg*-infected fibroblasts, a variety of Rab-containing organelles, including Golgi and endocytic compartments, are sequestered in the PV, allowing lipid acquisition by the parasite [46]. In DCs as well, the PV intersects with endocytic recycling compartments, resulting in accumulation of the Rab22a GTPase onto the PVM. In this case, this process seems to benefit the host as it promotes *Tg* MHC-I presentation [73]. Yet at this stage, beside effectors that generate the IVN [46], the effectors driving the PV-host organelle connections remain ill-defined. Furthermore, the exact implications of these new infection-related trafficking pathways on DC functions and parasite fitness remain to be studied.

Additional indirect mechanisms may contribute to the modulation of MHC-I presentation by the parasite. Of particular interest is the role of the ER-associated **unfolded protein response (UPR)** induced by viruses, bacteria and parasite infections [74]. UPR induction in DCs has recently been implicated in the modulation of MHC-I antigen presentation in normal and pathological conditions [75–77]. Interestingly, type I *Tg*ROP18 was reported to directly phosphorylate the host UPR sensor ATF6β, resulting in its degradation by the proteasome [78] (Figure 1c). DCs isolated from ATF6β KO mice exhibit a reduced ability to re-stimulate primed $CD8^+$ T cells, but not $CD4^+$ T cells, suggesting a yet unexplored function of ATF6β in MHC-I antigen presentation (Figure 2). However, since an enhanced IFN-γ production by $CD4^+$ T cells in mice infected with *Tg*ROP18 KO parasites was also observed, it is likely that additional mechanisms beyond the targeting of ATF6β-mediated **cross-presentation** dampen T cell activation [78]. Therefore, whether *Tg*ROP18 directly impacts on MHC-I presentation requires further investigation. Finally, it remains to be studied whether MHC-I

presentation is modulated during the chronic phase of the infection by persistent parasites present in tissues, such as the muscles, the retina and the central nervous system. Indeed, we have recently shown that MHC-I presentation of tachyzoite-derived antigens by neurons is pivotal for $CD8^+$ T cell-mediated parasite control in the brain [79]. However, it remains to be established if and how effectors secreted by bradyzoites interfere with MHC-I presentation, both in the target neuronal cells as well as in the surrounding DCs.

Modulation of MHC-II presentation by Tg

The manipulation of the MHC-II antigen presentation pathway by *Tg* tachyzoites has been reported both at steady-state and following IFN-γ stimulation (Box 3).

At steady-state, *Tg* promotes the accumulation of CD74/Ii in the ER of infected cells and reduces the transcription of H2-DM, a chaperone essential for MHC-II loading. These combined effects result in the inhibition of MHC-II presentation of parasite-derived antigens [80]. Accumulation of CD74 is triggered by type I and type II strains, requires invasion by live parasites (but not replication), and is observed in macrophages and cDC1 isolated from the LN of infected mice. In fact, *Tg* infection is known to impede IFN-γ-mediated upregulation of MHC-II in multiple cell types [81,82]. This is due to the ability of *Tg* to disturb chromatin remodeling at the class II transactivator CIITA locus [35] through the blockade of STAT1 activity (Figure 2) [83]. The parasite effector(s) responsible for this effect were reported to be rhoptry and/or dense granule-derived proteins [80]. *Tg*IST, which represses STAT1-dependent promoters, is thus a very likely candidate for the dysregulation of MHC-II molecule expression [36,37].

By preventing the upregulation of MHC-II on the surface of infected DCs, *Tg* alters the activation of $CD4^+$ T cells *in vivo* [84] and impedes parasite control. In agreement, $CD74^{-/-}$-H2-$DM^{-/-}$ KO mice fail to control infection by type II strains, correlating with high cerebral cyst burden, showing the important role of MHC-II antigen presentation during chronic toxoplasmosis [80]. In line,

326 immunization with the *Tg* AS15 peptide, a natural $CD4^+$ T cell antigen (Box 3), lowered cyst burden
327 and parasite load in the brain of infected mice [85].
328 Moreover, DCs deficient in the autophagy protein ATG5, but not ATG7, were reported to induce
329 diminished $CD4^+$ T cell production of IL-2 and IFN-γ after type II strain infection**,** suggesting that
330 non canonical autophagy may stimulate delivery of antigens to the MHC-II presentation pathway
331 (Box 2) [86,87]. In general, in contrast to macrophages, the role of autophagy in the modulation of
332 DC responses upon *Tg* infection remains mostly unexplored (Box 2).
333
334 *Modulation of DC maturation by Tg*
335 Contrasting results were obtained *in vitro* on the modulation of co-stimulatory molecule expression
336 following *Tg* infection. Infection by type I parasites leads to the activation of human DCs by
337 increasing the expression of CD40, CD80, CD86 and HLA-DR [26,88]. In contrast, immature
338 murine BMDCs are activated after exposure to HK parasites or STAg (increased CD40, CD80,
339 CD86 and MHC-II expression) but not after invasion by type I parasites, which also render them
340 resistant to subsequent activation by TLR ligands [84] (Figure 3). Importantly, Tait *et al.* reported
341 that infection by type I parasites is correlated with a decrease in the number of DCs in the PEC and
342 LN, compared to type II infection [89]. DCs recruited at the site of infection display a reduced
343 expression of CD80 and MHC-I compared to DCs analyzed during type II infection. As expected,
344 the diminished number of activated DCs altered the generation of specific $CD8^+$ T cell responses. In
345 addition, IL-12 treatment during type I infection only modestly increased the number of antigen-
346 specific $CD8^+$ T cells, reinforcing the hypothesis that type I parasites restrict $CD8^+$ T cell priming.
347 The observed DC reduction upon type I infection may be a result of parasite-triggered cell death or
348 impaired recruitment in response to altered chemokine environment. Overall, this may well explain
349 the higher virulence of type I strains in comparison to type II strains and suggest that type II parasite
350 virulence may be efficiently controlled by murine DCs. Supporting this hypothesis, systemic

infection of mice by type II parasites resulted in increased expression of CD40, CD80, CD86 and MHC-II markers and elevated IL-12 production by both $CD8\alpha^-$ and $CD8\alpha^+$ splenic DCs [90] (Figure 3). In addition, CD40-CD154 interactions were found to be essential to maintain splenic DC activation during infection [90]. In agreement, CD40 is upregulated in cDC1 following STAg injection in mice [91]. Therefore, strain-dependent modulation of DC maturation appears critical to shape the generation of *Tg* antigen-specific T cells and determine the outcome of infection in mice. Nonetheless, the precise mechanisms by which the parasite interferes with key DC functions, such as antigen presentation, DC maturation and survival need to be elucidated. Also, an improved characterization of *Tg* antigen presentation pathways in human DCs as well as in distinct tissue-resident DC subtypes is an important goal for future studies.

Tg modulation of DC migratory functions

Pioneer experiments suggested that DCs and monocytes participate to the transport of the parasite from the primary site of infection and are used as "Trojan horses" to enhance rapid parasite dissemination towards distant organs [92]. This phenomenon likely complements the ability of the parasites to exploit cerebral endothelial cells as a replication niche and a direct portal of entry into the brain parenchyma [93].

Supporting the "Trojan horse' hypothesis", type I strain-infected murine BMDCs display enhanced ability to disseminate *in vivo* compared to free tachyzoites [94]. Phagocytosis of HK parasites or incubation with *Tg* secretory fraction do not enhance migration of DCs *in vitro* [94,95] suggesting a modulation of host signaling by secreted effectors. In line, DCs infected by type II parasites, but not bystander cells, migrate significantly longer distances compared to type I-infected DCs in a 3D matrix [96]. Similarly, an enrichment of migratory type II-infected DCs compared to type I strain-infected DCs was monitored in spleen and MLN 16 hours after inoculation of pre-infected BMDCs [95]. Importantly, infection of monocytes, NK, B and T cells fail to induce an enhanced migratory

phenotype [97], indicating a DC-specific modulation of host responses by the parasite via regulatory mechanisms that have been partially uncovered and recently expertly reviewed [98]. It is proposed that a transition from mesenchymal to amoeboid migration mode enables high-speed locomotion of the parasite through interstitial tissues and across biological barriers, which in conjunction with enhanced chemotaxis, promotes *Tg* dissemination **(**Box 4**).**

Nonetheless, parasite effectors that stimulate the migratory ability of DCs need to be characterized. *Tg*GRA5, secreted and inserted at the PVM during parasite intracellular replication, was identified as a factor stimulating migration of human DCs *in vitro* [99]. The authors further pinpointed a peptide derived from the type I-*Tg*GRA5 hydrophilic N-terminal region, which, after internalization by micropinocytosis, triggers the expression of CCR7 and enhances DC directional migration via a JNK-dependent signaling [99]. However, how this peptide acts at the PVM during infection by live parasites remains to be determined. In addition to *Tg*GRA5, *Tg*14-3-3, a protein located in the vacuolar space, was shown to induce *in vitro* DC hypermotility and enhanced chemotaxis via an unknown mechanism that may involve sequestration of host 14-3-3 at the PVM [100] (Figure 3). Thus, it is likely that a synergistic effect of several parasite effectors contribute to the modulation of distinct signaling pathways and transcriptional responses altering DC migration. The identification and subsequent depletion of these effectors will provide a useful mean to assess the importance of parasite-driven activation of DC migration in *Tg* virulence and the establishment of latent infections in mice. Noteworthy, after intraperitoneal type I parasite injection, *Tg* was reported to preferentially target pDCs in the peritoneum and to enhance their migration towards the marginal zone and T cell areas of the spleen. This process was found to be partially dependent on CCR2 [101]. Therefore, further *in vivo* investigations are required to clearly identify which DC subset(s) are targeted by the parasite at the site of infection after oral infection [8], and whether a differential impact on DC migratory functions is observed in an *in vivo* context between type I and type II parasites.

Concluding remarks

DCs critically bridge innate and adaptive immunity through their capacity to sense microbial compounds and drive antigen-specific T cell activation. DCs perform this task by patrolling tissues in search of danger signals, by antigen presentation, and by secreting immuno-modulatory cytokines that shape innate and adaptive immune responses. Hence, it is assumed that any manipulation of these key activities by the parasite may directly impact on parasite dissemination or persistence. A growing body of evidence suggests that the parasite targets each of these processes (summarized in Figure 3). In laboratory mice, type I strain infection results in uncontrolled parasite growth, rapid dissemination and detrimental tissue inflammation that eventually kills the host. In contrast, type II parasite burden and inflammation are kept under control, allowing latent infections to establish in organs distant from the gut, the primary site of parasite entry. While a growing list of parasite effectors modulating host responses in macrophages and monocytes has been characterized, only a few were identified as possibly manipulating DC functions. It is likely that effectors previously identified in other cell types may hijack similar host pathways in DCs, notably *Tg*GRA24 [102], which targets the p38 MAPK signaling and *Tg*IST, which impairs STAT1-mediated ISG transcription [37]. However, it is also possible that certain *Tg* effectors exert specific functions in DCs (see Outstanding Questions). Importantly, the genetic polymorphisms of some effectors delineates the hyper-virulence of type I strain *versus* the latency of avirulent type II strains in mice, with a major impact of type I parasite-mediated modulation of cell-autonomous immunity. However, the ability of the different DC subsets to kill or restrict parasite growth remains elusive. This may have major consequences on the stimulation of distinct *Tg* innate sensing mechanisms. Whether *Tg* manipulates PRR-mediated detection of *Tg* PAMPs and thereby the downstream pathways controlled by PRR stimulation, needs to be explored.

DCs exhibit specialized trafficking pathways (e.g. dedicated for cross-presentation), it is thus possible that DC-specific *Tg* effectors hijack such pathways to support their intracellular lifestyle.

Up to now, no type II-specific effector that manipulates host cell responses to eventually promote parasite latency and host maintenance has been identified. Hence, identifying the key DC subsets operating in the gut of orally infected mice or the brain and muscular tissues during parasite latency, and the characterization of their responses upon virulent *versus* latent infection are important goals for future studies. Based on the specificity of DC functions compared to macrophages, in-depth exploration of DC-*Toxoplasma* interactions is needed to open novel therapeutic avenues that would reduce inflammation-induced pathology and boost antigen-specific T cell responses, which could ultimately ameliorate the clinical outcome of cerebral chronic toxoplasmosis.

References

1 Sibley, L.D. *et al.* (2009) Genetic diversity of Toxoplasma gondii in animals and humans. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* 364, 2749–2761

2 Fuglewicz, A. *et al.* (2017) Relationship between toxoplasmosis and schizophrenia: A review. *Adv. Clin. Exp. Med.* 26, 1033–1038

3 Bayani, M. *et al.* (2019) Toxoplasma gondii infection and risk of Parkinson and Alzheimer diseases: A systematic review and meta-analysis on observational studies. *Acta Trop.* 196, 165–171

4 Hassan, M.A. *et al.* (2019) Clonal and atypical Toxoplasma strain differences in virulence vary with mouse sub-species. *Int. J. Parasitol.* 49, 63–70

5 Murillo-León, M. *et al.* (2019) Molecular mechanism for the control of virulent Toxoplasma gondii infections in wild-derived mice. *Nat. Commun.* 10,

6 Hakimi, M.-A. *et al.* (2017) Toxoplasma Effectors Targeting Host Signaling and Transcription. *Clin. Microbiol. Rev.* 30, 615–645

449 7 Lima, T.S. and Lodoen, M.B. (2019) Mechanisms of Human Innate Immune Evasion by
450 Toxoplasma gondii. *Front. Cell. Infect. Microbiol.* 9,
451 8 Cohen, S.B. and Denkers, E.Y. (2015) Impact of Toxoplasma gondii on Dendritic Cell Subset
452 Function in the Intestinal Mucosa. *J. Immunol. Baltim. Md 1950* 195, 2754–2762
453 9 Dupont, C.D. *et al.* (2012) Immune response and immunopathology during toxoplasmosis.
454 *Semin. Immunopathol.* 34, 793–813
455 10 Liu, C.-H. *et al.* (2006) Cutting edge: dendritic cells are essential for in vivo IL-12 production
456 and development of resistance against Toxoplasma gondii infection in mice. *J. Immunol.*
457 *Baltim. Md 1950* 177, 31–35
458 11 Hou, B. *et al.* (2011) Critical coordination of innate immune defense against Toxoplasma
459 gondii by dendritic cells responding via their Toll-like receptors. *Proc. Natl. Acad. Sci. U. S. A.*
460 108, 278–283
461 12 Raetz, M. *et al.* (2013) Cooperation of TLR12 and TLR11 in the IRF8-dependent IL-12
462 response to Toxoplasma gondii profilin. *J. Immunol. Baltim. Md 1950* 191, 4818–4827
463 13 Pifer, R. *et al.* (2011) UNC93B1 is essential for TLR11 activation and IL-12-dependent host
464 resistance to Toxoplasma gondii. *J. Biol. Chem.* 286, 3307–3314
465 14 Yarovinsky, F. *et al.* (2005) TLR11 activation of dendritic cells by a protozoan profilin-like
466 protein. *Science* 308, 1626–1629
467 15 Plattner, F. *et al.* (2008) Toxoplasma profilin is essential for host cell invasion and TLR11-
468 dependent induction of an interleukin-12 response. *Cell Host Microbe* 3, 77–87
469 16 Koblansky, A.A. *et al.* (2013) Recognition of profilin by Toll-like receptor 12 is critical for host
470 resistance to Toxoplasma gondii. *Immunity* 38, 119–130
471 17 Melo, M.B. *et al.* (2010) UNC93B1 mediates host resistance to infection with Toxoplasma
472 gondii. *PLoS Pathog.* 6, e1001071

18 Debierre-Grockiego, F. *et al.* (2007) Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii. *J. Immunol. Baltim. Md 1950* 179, 1129–1137

19 Scanga, C.A. *et al.* (2002) Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. *J. Immunol. Baltim. Md 1950* 168, 5997–6001

20 Sardinha-Silva, A. *et al.* (2017) Toxoplasma gondii microneme proteins 1 and 4 bind to Toll-like receptors 2 and 4 N-glycans triggering innate immune response. *bioRxiv* DOI: 10.1101/187690

21 Dietrich, N. *et al.* (2010) Murine toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments. *PloS One* 5, e10250

22 Corridoni, D. *et al.* (2019) NOD2 and TLR2 Signal via TBK1 and PI31 to Direct Cross-Presentation and CD8 T Cell Responses. *Front. Immunol.* 10, 958

23 Minns, L.A. *et al.* (2006) TLR9 is required for the gut-associated lymphoid tissue response following oral infection of Toxoplasma gondii. *J. Immunol. Baltim. Md 1950* 176, 7589–7597

24 Benson, A. *et al.* (2009) Gut commensal bacteria direct a protective immune response against Toxoplasma gondii. *Cell Host Microbe* 6, 187–196

25 Heimesaat, M.M. *et al.* (2007) Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. *Gut* 56, 941–948

26 Subauste, C.S. and Wessendarp, M. (2000) Human dendritic cells discriminate between viable and killed Toxoplasma gondii tachyzoites: dendritic cell activation after infection with viable parasites results in CD28 and CD40 ligand signaling that controls IL-12-dependent and -independent T cell production of IFN-gamma. *J. Immunol. Baltim. Md 1950* 165, 1498–1505

27 Tosh, K.W. *et al.* (2016) The IL-12 Response of Primary Human Dendritic Cells and Monocytes to Toxoplasma gondii Is Stimulated by Phagocytosis of Live Parasites Rather Than Host Cell Invasion. *J. Immunol. Baltim. Md 1950* 196, 345–356

28 Pauwels, A.-M. *et al.* (2017) Patterns, Receptors, and Signals: Regulation of Phagosome Maturation. *Trends Immunol.* 38, 407–422

29 Silva, V.O. *et al.* (2018) Extracellular vesicles isolated from Toxoplasma gondii induce host immune response. *Parasite Immunol.* 40, e12571

30 Li, Y. *et al.* (2018) Characterization of exosomes derived from Toxoplasma gondii and their functions in modulating immune responses. *Int. J. Nanomedicine* 13, 467–477

31 Christian, D.A. *et al.* (2014) Use of transgenic parasites and host reporters to dissect events that promote interleukin-12 production during toxoplasmosis. *Infect. Immun.* 82, 4056–4067

32 Saeij, J.P. and Frickel, E.-M. (2017) Exposing Toxoplasma gondii hiding inside the vacuole: a role for GBPs, autophagy and host cell death. *Curr. Opin. Microbiol.* 40, 72–80

33 Lee, Y. *et al.* (2015) p62 Plays a Specific Role in Interferon-γ-Induced Presentation of a Toxoplasma Vacuolar Antigen. *Cell Rep.* 13, 223–233

34 Schneider, A.G. *et al.* (2013) Toxoplasma gondii triggers phosphorylation and nuclear translocation of dendritic cell STAT1 while simultaneously blocking IFNγ-induced STAT1 transcriptional activity. *PloS One* 8, e60215

35 Lang, C. *et al.* (2012) Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-γ. *PLoS Pathog.* 8, e1002483

36 Olias, P. *et al.* (2016) Toxoplasma Effector Recruits the Mi-2/NuRD Complex to Repress STAT1 Transcription and Block IFN-γ-Dependent Gene Expression. *Cell Host Microbe* 20, 72–82

520 37 Gay, G. *et al.* (2016) Toxoplasma gondii TgIST co-opts host chromatin repressors dampening
521 STAT1-dependent gene regulation and IFN-γ-mediated host defenses. *J. Exp. Med.* 213, 1779–
522 1798
523 38 Rosowski, E.E. and Saeij, J.P.J. (2012) Toxoplasma gondii clonal strains all inhibit STAT1
524 transcriptional activity but polymorphic effectors differentially modulate IFNγ induced gene
525 expression and STAT1 phosphorylation. *PloS One* 7, e51448
526 39 Rosowski, E.E. *et al.* (2011) Strain-specific activation of the NF-kappaB pathway by GRA15, a
527 novel Toxoplasma gondii dense granule protein. *J. Exp. Med.* 208, 195–212
528 40 Gov, L. *et al.* (2013) Human innate immunity to Toxoplasma gondii is mediated by host
529 caspase-1 and ASC and parasite GRA15. *mBio* 4,
530 41 Gorfu, G. *et al.* (2014) Dual role for inflammasome sensors NLRP1 and NLRP3 in murine
531 resistance to Toxoplasma gondii. *mBio* 5,
532 42 Schlee, M. and Hartmann, G. (2016) Discriminating self from non-self in nucleic acid sensing.
533 *Nat. Rev. Immunol.* 16, 566–580
534 43 Pernas, L. *et al.* (2014) Toxoplasma effector MAF1 mediates recruitment of host mitochondria
535 and impacts the host response. *PLoS Biol.* 12, e1001845
536 44 Wijdeven, R.H. *et al.* (2015) ER contact sites direct late endosome transport. *BioEssays News*
537 *Rev. Mol. Cell. Dev. Biol.* 37, 1298–1302
538 45 Cabukusta, B. and Neefjes, J. (2018) Mechanisms of lysosomal positioning and movement.
539 *Traffic Cph. Den.* 19, 761–769
540 46 Romano, J.D. *et al.* (2017) The parasite Toxoplasma sequesters diverse Rab host vesicles
541 within an intravacuolar network. *J. Cell Biol.* 216, 4235–4254
542 47 Napolitano, A. *et al.* (2018) Cysteine-Reactive Free ISG15 Generates IL-1β-Producing CD8α+
543 Dendritic Cells at the Site of Infection. *J. Immunol. Baltim. Md 1950* 201, 604–614

544 48 Beiting, D.P. (2014) Protozoan parasites and type I interferons: a cold case reopened. *Trends*
545 *Parasitol.* 30, 491–498
546 49 Silva-Barrios, S. and Stäger, S. (2017) Protozoan Parasites and Type I IFNs. *Front. Immunol.* 8,
547 50 Pepper, M. *et al.* (2008) Plasmacytoid dendritic cells are activated by Toxoplasma gondii to
548 present antigen and produce cytokines. *J. Immunol. Baltim. Md 1950* 180, 6229–6236
549 51 Han, S.-J. *et al.* (2014) Internalization and TLR-dependent type I interferon production by
550 monocytes in response to Toxoplasma gondii. *Immunol. Cell Biol.* 92, 872–881
551 52 Orellana, M.A. *et al.* (1991) Role of beta interferon in resistance to Toxoplasma gondii
552 infection. *Infect. Immun.* 59, 3287–3290
553 53 Mattei, F. *et al.* (2009) Type I IFN regulate DC turnover in vivo. *Eur. J. Immunol.* 39, 1807–
554 1818
555 54 Pantel, A. *et al.* (2014) Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is
556 required for maturation and metabolic shift to glycolysis after poly IC stimulation. *PLoS Biol.*
557 12, e1001759
558 55 Schiavoni, G. *et al.* (2013) Type I Interferons as Stimulators of DC-Mediated Cross-Priming:
559 Impact on Anti-Tumor Response. *Front. Immunol.* 4, 483
560 56 Couturier-Maillard, A. *et al.* (2018) Interleukin-22-deficiency and microbiota contribute to the
561 exacerbation of Toxoplasma gondii-induced intestinal inflammation. *Mucosal Immunol.* 11,
562 1181–1190
563 57 Ryffel, B. *et al.* (2019) Blockade of IL-33R/ST2 Signaling Attenuates Toxoplasma gondii
564 Ileitis Depending on IL-22 Expression. *Front. Immunol.* 10, 702
565 58 Blander, J.M. (2018) Regulation of the Cell Biology of Antigen Cross-Presentation. *Annu. Rev.*
566 *Immunol.* 36, 717–753
567 59 Iwasaki, A. and Medzhitov, R. (2010) Regulation of adaptive immunity by the innate immune
568 system. *Science* 327, 291–295

569 60 Nair-Gupta, P. *et al.* (2014) TLR signals induce phagosomal MHC-I delivery from the
570 endosomal recycling compartment to allow cross-presentation. *Cell* 158, 506–521
571 61 Gros, M. and Amigorena, S. (2019) Regulation of Antigen Export to the Cytosol During Cross-
572 Presentation. *Front. Immunol.* 10, 41
573 62 Kwok, L.-Y. *et al.* (2003) The induction and kinetics of antigen-specific CD8 T cells are
574 defined by the stage specificity and compartmentalization of the antigen in murine
575 toxoplasmosis. *J. Immunol. Baltim. Md 1950* 170, 1949–1957
576 63 Gregg, B. *et al.* (2011) Subcellular antigen location influences T-cell activation during acute
577 infection with Toxoplasma gondii. *PloS One* 6, e22936
578 64 Dupont, C.D. *et al.* (2014) Parasite fate and involvement of infected cells in the induction of
579 CD4+ and CD8+ T cell responses to Toxoplasma gondii. *PLoS Pathog.* 10, e1004047
580 65 Grover, H.S. *et al.* (2014) Impact of regulated secretion on antiparasitic CD8 T cell responses.
581 *Cell Rep.* 7, 1716–1728
582 66 Gubbels, M.-J. *et al.* (2005) Class I major histocompatibility complex presentation of antigens
583 that escape from the parasitophorous vacuole of Toxoplasma gondii. *Infect. Immun.* 73, 703–
584 711
585 67 Blanchard, N. *et al.* (2008) Immunodominant, protective response to the parasite Toxoplasma
586 gondii requires antigen processing in the endoplasmic reticulum. *Nat. Immunol.* 9, 937–944
587 68 Goldszmid, R.S. *et al.* (2009) Host ER-parasitophorous vacuole interaction provides a route of
588 entry for antigen cross-presentation in Toxoplasma gondii-infected dendritic cells. *J. Exp. Med.*
589 206, 399–410
590 69 Cebrian, I. *et al.* (2011) Sec22b regulates phagosomal maturation and antigen crosspresentation
591 by dendritic cells. *Cell* 147, 1355–1368

592 70 Buaillon, C. *et al.* (2017) MHC I presentation of Toxoplasma gondii immunodominant antigen
593 does not require Sec22b and is regulated by antigen orientation at the vacuole membrane. *Eur.*
594 *J. Immunol.* 47, 1160–1170
595 71 Feliu, V. *et al.* (2013) Location of the CD8 T cell epitope within the antigenic precursor
596 determines immunogenicity and protection against the Toxoplasma gondii parasite. *PLoS*
597 *Pathog.* 9, e1003449
598 72 Lopez, J. *et al.* (2015) Intravacuolar Membranes Regulate CD8 T Cell Recognition of
599 Membrane-Bound Toxoplasma gondii Protective Antigen. *Cell Rep.* 13, 2273–2286
600 73 Cebrian, I. *et al.* (2016) Rab22a controls MHC-I intracellular trafficking and antigen cross-
601 presentation by dendritic cells. *EMBO Rep.* 17, 1753–1765
602 74 Galluzzi, L. *et al.* (2017) Endoplasmic reticulum stress and unfolded protein response in
603 infection by intracellular parasites. *Future Sci. OA* 3, FSO198
604 75 Cubillos-Ruiz, J.R. *et al.* (2015) ER Stress Sensor XBP1 Controls Anti-tumor Immunity by
605 Disrupting Dendritic Cell Homeostasis. *Cell* 161, 1527–1538
606 76 Grootjans, J. *et al.* (2016) The unfolded protein response in immunity and inflammation. *Nat.*
607 *Rev. Immunol.* 16, 469–484
608 77 Osorio, F. *et al.* (2018) Antigen presentation unfolded: identifying convergence points between
609 the UPR and antigen presentation pathways. *Curr. Opin. Immunol.* 52, 100–107
610 78 Yamamoto, M. *et al.* (2011) ATF6beta is a host cellular target of the Toxoplasma gondii
611 virulence factor ROP18. *J. Exp. Med.* 208, 1533–1546
612 79 Salvioni, A. *et al.* (2019) Robust Control of a Brain-Persisting Parasite through MHC I
613 Presentation by Infected Neurons. *Cell Rep.* 27, 3254-3268.e8
614 80 Leroux, L.-P. *et al.* (2015) Parasite Manipulation of the Invariant Chain and the Peptide Editor
615 H2-DM Affects Major Histocompatibility Complex Class II Antigen Presentation during
616 Toxoplasma gondii Infection. *Infect. Immun.* 83, 3865–3880

617 81 Lüder, C.G.K. *et al.* (2003) Toxoplasma gondii inhibits MHC class II expression in neural
618 antigen-presenting cells by down-regulating the class II transactivator CIITA. *J.*
619 *Neuroimmunol.* 134, 12–24
620 82 Lang, C. *et al.* (2006) Diverse mechanisms employed by Toxoplasma gondii to inhibit IFN-γ-
621 induced major histocompatibility complex class II gene expression. *Microbes Infect.* 8, 1994–
622 2005
623 83 Kim, S.-K. *et al.* (2007) Toxoplasma gondii Dysregulates IFN-γ-Inducible Gene Expression in
624 Human Fibroblasts: Insights from a Genome-Wide Transcriptional Profiling. *J. Immunol.* 178,
625 5154–5165
626 84 McKee, A.S. *et al.* (2004) Functional inactivation of immature dendritic cells by the
627 intracellular parasite Toxoplasma gondii. *J. Immunol. Baltim. Md 1950* 173, 2632–2640
628 85 Grover, H.S. *et al.* (2012) The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can
629 control parasite burden. *Infect. Immun.* 80, 3279–3288
630 86 Liu, E. *et al.* (2015) Atg5 but not Atg7 in dendritic cells enhances IL-2 and IFN-γ production
631 by Toxoplasma gondii-reactive CD4+ T cells. *Microbes Infect.* 17, 275–284
632 87 Lee, H.K. *et al.* (2010) In vivo requirement for Atg5 in antigen presentation by dendritic cells.
633 *Immunity* 32, 227–239
634 88 Séguin, R. and Kasper, L.H. (1999) Sensitized lymphocytes and CD40 ligation augment
635 interleukin-12 production by human dendritic cells in response to Toxoplasma gondii. *J. Infect.*
636 *Dis.* 179, 467–474
637 89 Tait, E.D. *et al.* (2010) Virulence of Toxoplasma gondii is associated with distinct dendritic cell
638 responses and reduced numbers of activated CD8+ T cells. *J. Immunol. Baltim. Md 1950* 185,
639 1502–1512
640 90 Straw, A.D. *et al.* (2003) CD154 plays a central role in regulating dendritic cell activation
641 during infections that induce Th1 or Th2 responses. *J. Immunol. Baltim. Md 1950* 170, 727–734

642 91 Schulz, O. *et al.* (2000) CD40 triggering of heterodimeric IL-12 p70 production by dendritic
643 cells in vivo requires a microbial priming signal. *Immunity* 13, 453–462
644 92 Courret, N. *et al.* (2006) CD11c- and CD11b-expressing mouse leukocytes transport single
645 Toxoplasma gondii tachyzoites to the brain. *Blood* 107, 309–316
646 93 Konradt, C. *et al.* (2016) Endothelial cells are a replicative niche for entry of Toxoplasma
647 gondii to the central nervous system. *Nat. Microbiol.* 1, 16001
648 94 Lambert, H. *et al.* (2006) Induction of dendritic cell migration upon Toxoplasma gondii
649 infection potentiates parasite dissemination. *Cell. Microbiol.* 8, 1611–1623
650 95 Lambert, H. *et al.* (2009) The Toxoplasma gondii-shuttling function of dendritic cells is linked
651 to the parasite genotype. *Infect. Immun.* 77, 1679–1688
652 96 Kanatani, S. *et al.* (2015) Infection by Toxoplasma gondii Induces Amoeboid-Like Migration
653 of Dendritic Cells in a Three-Dimensional Collagen Matrix. *PloS One* 10, e0139104
654 97 Lambert, H. *et al.* (2011) Migratory responses of leukocytes infected with Toxoplasma gondii.
655 *Microbes Infect.* 13, 96–102
656 98 Bhandage, A.K. and Barragan, A. (2019) Calling in the CaValry-Toxoplasma gondii Hijacks
657 GABAergic Signaling and Voltage-Dependent Calcium Channel Signaling for Trojan horse-
658 Mediated Dissemination. *Front. Cell. Infect. Microbiol.* 9, 61
659 99 Persat, F. *et al.* (2012) A synthetic peptide derived from the parasite Toxoplasma gondii
660 triggers human dendritic cells' migration. *J. Leukoc. Biol.* 92, 1241–1250
661 100 Weidner, J.M. *et al.* (2016) Migratory activation of parasitized dendritic cells by the protozoan
662 Toxoplasma gondii 14-3-3 protein. *Cell. Microbiol.* 18, 1537–1550
663 101 Bierly, A.L. *et al.* (2008) Dendritic cells expressing plasmacytoid marker PDCA-1 are Trojan
664 horses during Toxoplasma gondii infection. *J. Immunol. Baltim. Md 1950* 181, 8485–8491

665 102 Braun, L. *et al.* (2013) A Toxoplasma dense granule protein, GRA24, modulates the early
666 immune response to infection by promoting a direct and sustained host p38 MAPK activation.
667 *J. Exp. Med.* 210, 2071–2086
668 103 Dalod, M. *et al.* (2014) Dendritic cell maturation: functional specialization through signaling
669 specificity and transcriptional programming. *EMBO J.* 33, 1104–1116
670 104 Evans, R.J. *et al.* (2018) The Interplay of Host Autophagy and Eukaryotic Pathogens. *Front.*
671 *Cell Dev. Biol.* 6, 118
672 105 Subauste, C.S. (2019) Interplay Between Toxoplasma gondii, Autophagy, and Autophagy
673 Proteins. *Front. Cell. Infect. Microbiol.* 9, 139
674 106 Corcino, Y.L. *et al.* (2019) Epidermal growth factor receptor promotes cerebral and retinal
675 invasion by Toxoplasma gondii. *Sci. Rep.* 9, 669
676 107 Ghislat, G. and Lawrence, T. (2018) Autophagy in dendritic cells. *Cell. Mol. Immunol.* 15, 944–
677 952
678 108 Wang, Y. *et al.* (2009) Host cell autophagy is induced by Toxoplasma gondii and contributes to
679 parasite growth. *J. Biol. Chem.* 284, 1694–1701
680 109 Yarovinsky, F. *et al.* (2006) Toll-like receptor recognition regulates immunodominance in an
681 antimicrobial CD4+ T cell response. *Immunity* 25, 655–664
682 110 Draheim, M. *et al.* (2017) Profiling MHC II immunopeptidome of blood-stage malaria reveals
683 that cDC1 control the functionality of parasite-specific CD4 T cells. *EMBO Mol. Med.* 9, 1605–
684 1621
685 111 Fuks, J.M. *et al.* (2012) GABAergic signaling is linked to a hypermigratory phenotype in
686 dendritic cells infected by Toxoplasma gondii. *PLoS Pathog.* 8, e1003051
687 112 Kanatani, S. *et al.* (2017) Voltage-dependent calcium channel signaling mediates GABAA
688 receptor-induced migratory activation of dendritic cells infected by Toxoplasma gondii. *PLoS*
689 *Pathog.* 13, e1006739

113 Ólafsson, E.B. *et al.* (2018) Toxoplasma gondii infection shifts dendritic cells into an amoeboid rapid migration mode encompassing podosome dissolution, secretion of TIMP-1, and reduced proteolysis of extracellular matrix. *Cell. Microbiol.* 20,

114 Weidner, J.M. *et al.* (2013) Rapid cytoskeleton remodelling in dendritic cells following invasion by Toxoplasma gondii coincides with the onset of a hypermigratory phenotype. *Cell. Microbiol.* 15, 1735–1752

Glossary

Active invasion: *Toxoplasma gondii* invades host cells by secreting effectors (rhoptry and microneme proteins) that enable parasite adhesion to the host plasma membrane and penetration into the forming vacuole.

Cross-presentation: refers to the presentation by MHC-I molecules of peptides derived from an extracellular source (from endocytosed proteins or microorganisms internalized through phagocytosis or after active invasion).

Dense granule (GRA): specific apicomplexan secretory organelle containing proteins involved in the maturation of the parasitophorous vacuole, the formation of the intravacuolar network and the modulation of host cell responses when secreted beyond the vacuole limiting membrane.

Endolysosome: intracellular organelle resulting from the fusion of a lysosome with an endocytic vesicle.

Endoplasmic reticulum (ER): A network of membranous tubules within the cytoplasm continuous with the nuclear membrane involved in protein and lipid synthesis and cellular homeostasis.

Exosome: extracellular vesicle originated from the endocytic compartment involved in cell to cell communication.

Immunity-related GTPase (IRG) and guanylate-binding proteins (GBP): GTPases induced upon interferon gamma stimulation, which accumulate at the parasite vacuole limiting membrane and trigger its degradation.

Inflammasome: intracellular multiprotein complex that detects microorganisms and other stressors, which activates IL-1β and IL-18 production. It also induces a form of cell death called pyroptosis.

Intravacuolar network (IVN): network of membrane tubules and vesicles present into the vacuolar space of the parasitophorous vacuole that interconnect the parasites and also connect the parasites to the vacuole limiting membrane.

Parasitophorous vacuole (PV): intracellular vacuole in which the parasites replicate protected from the host defense mechanisms.

Pathogen-associated molecular pattern (PAMP): small molecular motifs found in microbial molecules recognized by pattern recognition receptors.

Pattern recognition receptor (PRR): host sensors that detect PAMPs and trigger signaling pathways involved in innate immune responses.

Phagocytosis: mechanism by which phagocytes engulf and digest large particles and microorganisms.

Rhoptry (ROP): specific apicomplexan secretory organelle containing proteins involved in parasite invasion, PV formation and modulation of host cell responses.

Unfolded protein response (UPR): ER stress response induced by an accumulation of misfolded proteins in the ER, changes in lipid homeostasis, TLR stimulation and oxidative stresses. It is characterized by the activation of three ER sensors: ATF6, PERK and IRE1α which induce transcriptional programs aiming to restore cell homeostasis but can lead to the induction of cell apoptosis.

738 **Box 1: Dendritic cell functions and subsets**

739 Dendritic cells (DCs) represent an efficient patrolling system sampling tissues in search of danger
740 signals, and a first line of defense against invading pathogens. At steady-state, DCs reside in
741 immature or semi-mature states in the periphery, where they constantly take up and process self-
742 antigens to maintain self-tolerance. In response to infection, DCs undergo a program of maturation
743 involving the upregulation of Major Histocompatibility Complex (MHC) and co-stimulatory
744 molecules at the cell surface, the CCR7-dependent migration to T-cell-rich zones of secondary
745 lymphoid organs, and the release of cytokines promoting the differentiation of naïve T cells into
746 effector/memory cells, as well as the local activation of other immune cells [103]. Depending on the
747 nature of the microbial compounds they sense, DCs produce distinct cytokines and shape the
748 differentiation of different types of effector T cells, adapting T cell polarization to the specific threat.
749 Moreover, DCs bridge innate and adaptive immunity by presenting processed antigenic peptides on
750 MHC molecules to prime naïve antigen-specific T cells. DCs exist as functionally distinct subsets,
751 which can be distinguished based on their tissue distribution, cell surface markers, and
752 transcriptional programs (Table I).

753 **Table I. Dendritic cell subsets.**

DC subsets	Monocyte DC	cDC1	cDC2	pDC
Type	Migratory DC	Lymphoid resident DC ($CD8\alpha^+$) Migratory DC ($CD103^+$)	Lymphoid resident DC	Lymphoid resident DC
Mouse markers	$CD11b^+$ $Lyc6C^{hi/lo}$ $CD64^+$	$CD11c^+$ $MHC\text{-}II^+$ $XCR1^+$ $CLEC9A^+$ $FLT3^+$ $CD11b^-$ $CD8\alpha^+$ or $CD103^+$	$CD11c^+$ $MHC\text{-}II^+$ $CD11b^+$ $CD24^+$ $CD172a^+$ $CD8\alpha^-$	$CD11c^{int}$ $MHC\text{-}II^{int}$ $B220^+$ $PDCA1^+$ $SiglecH^+$ $Lyc6C^+$
Human markers	$CD11b^+$, $CD14^+$, $CD206^+$ $CD209^+$	$CD11c^{int}$ $MHC\text{-}II^+$ $XCR1^+$ $CLEC9A^+$ $FLT3^+$ $BDCA3^+$ $CD11b^-$	$CD11c^+$ $MHC\text{-}II^+$ $CD11b^+$ $CD172a^+$ $FLT3^+$ $BDCA1^+$	$CD11c^-$ $MHC\text{-}II^{int}$ $BDCA2^+$ $BDCA4^+$ $CD123^+$ $CD304^+$
Functions	TNF, iNOS and ROI production Presentation on MHC-II CD4 T cell response	Against intracellular pathogens IL12 production TLR3 induced Cross-presentation on MHC-I CD8 T cell response	Against extracellular pathogens IL12, TNFα production Presentation on MHC-II CD4 T cell response	IFN I/III, IL12, TNFα, IL6 production TLR7, TLR9 induced CD4 and CD8 T cell response

754

755 **Box 2: *Tg* modulation of autophagy in DCs**

756 Canonical autophagy is activated in *Tg*-infected cells upon CD40 signaling. This pathway is
757 dependent on ULK1, accompanied by LC3 accumulation onto the PV and it involves lysosomal
758 elimination of the parasite [104,105]. Autophagic targeting of *Tg* occurs in macrophages and
759 endothelial cells where it plays an important role in parasite restriction, in particular regarding access
760 to the neural tissue [106]. As a survival counter-strategy, *Tg* activates signaling cascades that
761 antagonize host autophagy through at least two distinct mechanisms, involving the activation of Akt
762 and the inhibition of PKR. In addition, some autophagy-related proteins are required for the
763 IRG/GBP-mediated restriction of *Tg* in the context of IFN-γ stimulated macrophages and fibroblasts.
764 However, these processes are distinct from *bona fide* autophagy, which typically involves fusion
765 with and degradation in lysosomes [104,105].
766 Autophagy regulates several DC functions including antigen presentation, cytokine production and
767 migration [107]. In *Tg*-infected DCs, the recruitment of autophagy protein at the PVM regulates
768 parasite antigen escape to the host cytosol and subsequent T cell activation [33,86,87], albeit in a
769 process that is likely not dependent on canonical autophagy [86,87]. Moreover, it is currently
770 unknown to which extent autophagy contributes to *Tg* parasite restriction in DCs and if autophagy
771 avoidance pathways are mobilized by the parasite in this cell type. Interestingly, host autophagy may
772 be hijacked by the parasite for the acquisition of nutrients to sustain its growth [108]. Knowing that
773 the PV in *Tg*-infected DCs intersects with various host organelles [46,68,69,73], it would be
774 interesting to investigate how the autophagosome-PV interplay regulates both the parasite and DC
775 metabolisms.
776

777 **Box 3: Mechanisms of MHC-II presentation by *T. gondii***

778 Two natural $CD4^+$ T cell antigens from *Tg* were described so far; the AS15 peptide derives from the
779 TgCD4Ag28m protein [85], predicted to be a secreted protein; the second one derives from *Tg*PRF
780 [109]. Based on the fact that the *Tg* CD4Ag28m-derived AS15 peptide is robustly presented even
781 when DC are fed with heat-killed parasites, it is likely that both secreted and non-secreted parasite
782 antigens have access to the MHC-II antigen degradative compartments where peptide loading on
783 MHC-II molecules occurs [85,110]. The mechanisms promoting antigen entry into the degradative
784 compartments in the case of replicating parasites residing in a vacuole are still elusive. DC deficient
785 in the autophagy protein ATG5, but not ATG7, induce diminished $CD4^+$ T cell production of IL-2
786 and IFN-γ after type II strain infection [86,87]. This defect is not accompanied by changes in MHC-
787 II and co-stimulatory molecule expression or impaired production of IL-12, IL-1β or TNF-α [86],
788 suggesting that it may be linked to a reduced delivery of antigens to the MHC-II presentation
789 pathway.
790
791 **Box 4: Modulation of DC migratory functions by *T. gondii***
792 *In vitro*, BMDC and human MDDC secrete GABA after infection with type I, II or III strains [111].
793 GABA secretion activates, via an autocrine effect, functional $GABA_A$ receptors, which induce the *in*
794 *vitro* transmigration and chemotaxis of type II infected murine DC and promote parasite
795 dissemination after their adoptive transfer in mice [111,112]. The signaling molecule calcium also
796 plays a central role for this migratory activation as signal transduction following GABAergic
797 activation is mediated via the L-type voltage-dependent calcium channel (L-VDCC) subtype $Ca_v1.3$.
798 More recently, the Barragan laboratory further identified a TIMP-1-CD63-ITGB1-FAK signaling
799 axis hijacked by *Tg* to drive high-speed amoeboid migration [113]. Moreover, infected DC enhanced
800 migration is preceded by morphological changes. Human and murine DCs infected by type II
801 parasites display cytoskeletal actin remodeling, exhibit a process of podosome dissolution and CD18
802 and CD11c integrin redistribution, thereby adopting an integrin-independent amoeboid-like motility

[96,114]. These morphological changes require parasite invasion of the DC but are independent of GABAergic signaling, in agreement with the hypermotility phenotype being independent of chemotactic cues [114]. In particular, the initial hypermotility phenotype of infected DCs does not depend on CCR7 or CCR5, but infected DCs up-regulate CCR7 to potentiate their chemotactic migration [111,114].

Legends

Figure 1, Key Figure: Innate sensing and modulation of signaling pathways in *Tg*-infected DCs. (a) Internalization of parasite debris, STAg (Soluble Tachyzoïte Antigen), *Tg*PRF (*Tg* profilin) or *Tg* exosomes stimulate IRF8-mediated production of IL-12 via a TLR11/12 and MyD88-dependent pathway in mice. **(b)** Phagocytosis of live or killed parasites results in TLR (Toll Like Receptors) activation after phagolysosomal fusion. TLR11 and TL12 play a major role in triggering cytokine response in mice. However, other endosomal TLRs, such as TLR 3/7/8/9 may be also stimulated, notably in human DCs, which lack functional TLR11 and TLR12 genes. Parasite degradation and partial disruption of the phagosomal membrane may lead to the release of RNA/DNA from the parasite sensed by cytosolic PRRs (Pattern Recognition Receptors) described to induce type I IFN production. **(c)** Innate sensing of type I parasites that have actively invaded DC relies on MyD88-dependent activation of TLRs, yet to be fully uncovered. Possible additional mechanisms may involve the RIG-1 and STING sensors localized at the host mitochondria and Endoplasmic Reticulum, respectively, two compartments tightly associated with the parasitophorous vacuole (PV). IFN-γ stimulation triggers the phosphorylation of STAT1, but the transcriptional activation of Interferon-stimulated gene (ISG), notably IRGs, is impaired in type I-infected DC, likely by a *Tg*IST-mediated process. The *Tg* ROP5/17/18 effectors also block IRG (Immune-Related GTPases)-induced vacuole damage upon IFN-γ stimulation, while *Tg* ROP18 (*Tg* ROP18) triggers ATF6β phosphorylation and degradation, resulting in decreased $CD8^+$ T cell activation. Also, MHC-

I, MHC-II and co-stimulatory molecule surface expression are down-regulated by type I parasites. **(d)** The innate sensing of type II parasites also relies on MyD88-dependent activation of TLR. Distinct sensing mechanisms compared to type I parasites may be induced, correlating with partial vacuole disruption. Upon IFNγ stimulation, PV damage and antigen escape to the cytosol is mediated by autophagy proteins (ATG and p62) and IRG / GBP recruitment at the PV membrane. Other ISG genes may be also induced in a *Tg*GRA15II- and NFκB-dependent manner. Possible leakage of parasite RNA/DNA upon PV disruption may activate cytosolic PRRs. In addition, ISG15 induces IL-1β production in infected cDC1. A putative activation of the inflammasome has not been investigated. Type II infection itself also triggers the phosphorylation of STAT1 but *Tg*IST effector likely reduces STAT1-mediated IRG/GBP expression. *Tg*IST is also likely involved in the down-regulation of MHC-II molecule surface expression upon IFN-γ stimulation.

Figure 2: Modulation of antigen presentation by *Tg* effectors. The intravacuolar tubulovesicular network (IVN) reduces GRA6 localization at the vacuole limiting membrane, therefore impeding access of the C-terminal fragment that contains the antigenic peptide into the host cytosol. This ultimately reduces presentation of the GRA6-derived peptide by MHC-I molecules on the cell surface. *Tg*ROP18 down-regulates CD8 T cell activation by a yet unknown mechanism that involves *Tg*ROP18-mediated phosphorylation and degradation of the ER sensor ATF6β. *Tg* infection represses H2-DM expression and induces CD74/li accumulation in the ER, thereby impairing MHC-II antigen presentation and CD4 T cell activation.

Figure 3. Modulation of DC functions during *Tg* infection. (a) Scheme summarizing the modulation of DC functions in mice infected by the *Tg* type I and type II strains during the different steps of the infection from parasite entry into the intestine, to their migration in secondary lymphoid organs. *Tg* parasites can also disseminate to distant organs such as the brain and muscles, possibly by

853 using DC as shuttle leucocytes or as extracellular parasites in the blood. For simplification,
854 modulations of human DC functions by the infection were not included in this figure. **(b)** Table
855 summarizing the functions of murine DCs that are up-regulated (red) or down-regulated (green)
856 compared to unchallenged DCs, by live *Tg* type I and type II strain infection, killed parasites or
857 STAgs. When identified, the parasite effectors and targeted host pathways were indicated, as well as
858 whether these findings were obtained *in vitro* in the context of differentiated or isolated murine DCs
859 (#) or *in vivo* in infected mice (§).


A
Endocytosis
T. gondii debris,
TgPRF, STAg
Exosomes
TLRs sensing
Late endosome
UNC93b1
dependent
TLR11/TLR12
MyD88 dependent
pathway
Endosomal
PRRs sensing
IRF8
Il12
B
Phagocytosis
T. gondii
Fusion
Lysosome
Phagosome
Phagolysosome
RNA, DNA
Cytosolic
sensing?
TLR11, 12 (mice)
TLR 3,7,8,9?
?
IFN-I ?
Inflammatory cytokines
C
Active invasion with type I
Type I T. gondii
TLRs sensing
RIG1/MAVS?
cGAS/STING?
IRGs
TgROP5/17/18
TgROP18
Proteosomal
degradation
p-ATF6β
p-STAT1
TgIST ?
IRGs, ISGs
MyD88
Il12
D
Active invasion with type II
Type II T. gondii
TLRs sensing
RIG1/MAVS?
cGAS/STING?
RNA, DNA
sensing?
vacuole
damage
p-ATF6β
?
TgROP18
IRGs
p62
Inflammasome?
TgIST ?
ISG15
TgGRA15
?
IRGs
Il1β
ISGs
MyD88
Il12
Legend:
T. gondii ROP protein
T. gondii GRA protein
CD80/86
CD40
MHC-I
MHC-II
Mitochondria
Endoplasmic reticulum


LT CD8+
GRA6 peptide
TCR
MHC-I
LT CD8+
LT CD4+
MHC-II
LT CD4+
?
Proteosomal
degradation
GRA6
CD74/Ii
accumulation
ROP18
ATF6β
Endoplasmic
Reticulum
IVN
nucleus
H2-DM
GRA6 associated to intravacuolar network
GRA6 associated to vacuolar membrane
Tg ROP proteins
Tg GRA proteins
CD74/Ii



B

Modulation of DC functions	Type I		Type II		Killed parasites	STAgs
	Tg effector	Host target / pathway	*Tg* effector	Host target		
IL12 secretion	*Tg*PRF #§ *Tg*MIC1/MIC4 # *Tg*Cyclophilin #	TLR11/12 #§ TLR2 # CCR5 #	*Tg*PRF #§ *Tg*Cyclophilin #	TLR11/12 #§ CCR5 #	#	#
IL1β secretion	nd	nd	§		nd	nd
STAT1 pathway	#		#		nd	nd
IFNγ-inducible gene transcription	*Tg*IST? #	STAT1 # MHC-II ? #	*Tg*IST? #	STAT1# MHC-II ? #	nd	nd
Co-stimulatory molecule expression	#§		§		#	#
T cell priming/activation	*Tg*ROP18 §	ATF6β §	#		nd	nd
Motility / Chemotaxis	*Tg*14-3-3 # *Tg*GRA5 #	GABAergic signaling# CCR7# TIMP-1-CD63-FAK #	#§		#	#

up | down | no modulation | nd : no data | #: *in vitro* | §: *in vivo*